- Home
- UBS vs AZN Comparison
UBS vs AZN Comparison
Compare UBS & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UBS | AZN |
|---|---|---|
| Founded | 1862 | 1992 |
| Country | Switzerland | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.1B | 316.4B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | UBS | AZN |
|---|---|---|
| Price | $49.73 | $178.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $60.30 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 1.9M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | 1.29% | ★ 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.40 | $10.34 |
| Revenue Next Year | $2.83 | $6.43 |
| P/E Ratio | ★ $17.22 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.39 | $68.62 |
| 52 Week High | $50.91 | $212.71 |
Technical Indicators
Market Signals| Indicator | UBS | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 64.09 | 43.36 |
| Support Level | $46.47 | $174.60 |
| Resistance Level | N/A | $191.50 |
| Average True Range (ATR) | 0.83 | 3.11 |
| MACD | 0.11 | -0.16 |
| Stochastic Oscillator | 72.39 | 31.44 |
Price Performance
Historical ComparisonAbout UBS UBS Group AG Registered
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.